Spruce Street Capital LP Acquires Shares of 4,059,054 Century Therapeutics, Inc. $IPSC

Spruce Street Capital LP bought a new stake in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 4,059,054 shares of the company's stock, valued at approximately $9,944,682,000. Century Therapeutics comprises approximately 2.0% of Spruce Street Capital LP's portfolio, making the stock its 16th largest holding. Spruce Street Capital LP owned approximately 2.25% of Century Therapeutics at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Prudential Financial Inc. bought a new position in shares of Century Therapeutics in the 2nd quarter worth $25,000. Bank of New York Mellon Corp bought a new stake in Century Therapeutics in the first quarter valued at about $29,000. Qube Research & Technologies Ltd acquired a new position in Century Therapeutics in the second quarter valued at about $38,000. Quadrant Private Wealth Management LLC lifted its stake in Century Therapeutics by 31.0% in the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company's stock valued at $45,000 after buying an additional 4,736 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Century Therapeutics during the second quarter worth about $51,000. Institutional investors and hedge funds own 50.20% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Mizuho initiated coverage on Century Therapeutics in a research note on Wednesday, May 27th. They issued an "outperform" rating and a $8.00 price target for the company. Wall Street Zen lowered shares of Century Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 27th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Century Therapeutics in a report on Thursday, July 2nd. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $4.75.

Century Therapeutics Stock Performance

NASDAQ:IPSC opened at $2.12 on Tuesday. The company has a market cap of $383.88 million, a PE ratio of -2.28 and a beta of 1.57. Century Therapeutics, Inc. has a 52-week low of $0.44 and a 52-week high of $3.04. The stock has a 50-day simple moving average of $2.17 and a 200 day simple moving average of $2.21.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.06). On average, research analysts predict that Century Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Century Therapeutics Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.

Want to see what other hedge funds are holding IPSC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source